Anixa Biosciences (ANIX) Stock Forecast, Price Target & Predictions
ANIX Stock Forecast
Anixa Biosciences stock forecast is as follows: an average price target of $8.00 (represents a 149.22% upside from ANIX’s last price of $3.21) and a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.
ANIX Price Target
The average price target for Anixa Biosciences (ANIX) is $8.00 based on 1-year price targets from 3 Wall Street analysts in the past 3 months, with a price target range of $8.00 to $8.00. This represents a potential 149.22% upside from ANIX's last price of $3.21.
ANIX Analyst Ratings
According to 3 Wall Street analysts, Anixa Biosciences's rating consensus is 'Buy'. The analyst rating breakdown for ANIX stock is 0 'Strong Buy' (0.00%), 3 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Anixa Biosciences Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Dec 23, 2022 | Matthew Barcus | Chardan Capital | $8.00 | $3.81 | 109.97% | 149.22% |
The latest Anixa Biosciences stock forecast, released on Dec 23, 2022 by Matthew Barcus from Chardan Capital, set a price target of $8.00, which represents a 109.97% increase from the stock price at the time of the forecast ($3.81), and a 149.22% increase from ANIX last price ($3.21).
Anixa Biosciences Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | - |
| Avg Price Target | - | - | - |
| Last Closing Price | $3.21 | $3.21 | $3.21 |
| Upside/Downside | -100.00% | -100.00% | -100.00% |
In the current month, the average price target of Anixa Biosciences stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Anixa Biosciences's last price of $3.21. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 07, 2024 | EF Hutton | - | Buy | Initialise |
| Jun 10, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Dec 23, 2022 | Chardan Capital | - | Buy | Initialise |
Anixa Biosciences's last stock rating was published by EF Hutton on Aug 07, 2024. The company Initialise its ANIX rating from "null" to "Buy".
Anixa Biosciences Financial Forecast
Anixa Biosciences Revenue Forecast
| Oct 25 | Jul 25 | May 25 | Jan 25 | Oct 24 | Jul 24 | Apr 24 | Apr 21 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - | $605.68K |
| High Forecast | - | - | - | - | - | - | - | $726.82K |
| Low Forecast | - | - | - | - | - | - | - | $484.54K |
| # Analysts | - | - | - | - | - | - | 1 | 10 |
| Surprise % | - | - | - | - | - | - | - | - |
Anixa Biosciences's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. ANIX's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
Anixa Biosciences EBITDA Forecast
| Oct 25 | Jul 25 | May 25 | Jan 25 | Oct 24 | Jul 24 | Apr 24 | Apr 21 | |
|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | 1 | 10 |
| EBITDA | - | - | - | - | - | - | - | $-2.42M |
| Avg Forecast | - | - | - | - | - | - | - | $-2.59M |
| High Forecast | - | - | - | - | - | - | - | $-2.07M |
| Low Forecast | - | - | - | - | - | - | - | $-3.11M |
| Surprise % | - | - | - | - | - | - | - | 0.93% |
undefined analysts predict ANIX's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Anixa Biosciences's previous annual EBITDA (undefined) of $NaN.
Anixa Biosciences Net Income Forecast
| Oct 25 | Jul 25 | May 25 | Jan 25 | Oct 24 | Jul 24 | Apr 24 | Apr 21 | |
|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | 1 | 10 |
| Net Income | - | - | - | - | - | - | - | $-2.40M |
| Avg Forecast | $-3.53M | $-3.53M | $-3.53M | $-3.53M | $-2.72M | $-2.72M | $-3.51M | $-2.61M |
| High Forecast | $-3.53M | $-3.53M | $-3.53M | $-3.53M | $-2.72M | $-2.72M | $-3.51M | $-2.09M |
| Low Forecast | $-3.53M | $-3.53M | $-3.53M | $-3.53M | $-2.72M | $-2.72M | $-3.51M | $-3.13M |
| Surprise % | - | - | - | - | - | - | - | 0.92% |
Anixa Biosciences's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. ANIX's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Anixa Biosciences SG&A Forecast
| Oct 25 | Jul 25 | May 25 | Jan 25 | Oct 24 | Jul 24 | Apr 24 | Apr 21 | |
|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | 1 | 10 |
| SG&A | - | - | - | - | - | - | - | $1.42M |
| Avg Forecast | - | - | - | - | - | - | - | $8.17M |
| High Forecast | - | - | - | - | - | - | - | $9.80M |
| Low Forecast | - | - | - | - | - | - | - | $6.53M |
| Surprise % | - | - | - | - | - | - | - | 0.17% |
Anixa Biosciences's average Quarter SG&A projection for Apr 24 is -, based on 1 Wall Street analysts, with a range of - to -. The forecast indicates a -100.00% fall compared to ANIX last annual SG&A of $1.42M (Apr 21).
Anixa Biosciences EPS Forecast
| Oct 25 | Jul 25 | May 25 | Jan 25 | Oct 24 | Jul 24 | Apr 24 | Apr 21 | |
|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | 1 | 10 |
| EPS | - | - | - | - | - | - | - | $-0.08 |
| Avg Forecast | $-0.11 | $-0.11 | $-0.11 | $-0.11 | $-0.09 | $-0.09 | $-0.11 | $-0.10 |
| High Forecast | $-0.11 | $-0.11 | $-0.11 | $-0.11 | $-0.09 | $-0.09 | $-0.11 | $-0.10 |
| Low Forecast | $-0.11 | $-0.11 | $-0.11 | $-0.11 | $-0.09 | $-0.09 | $-0.11 | $-0.10 |
| Surprise % | - | - | - | - | - | - | - | 0.80% |
According to undefined Wall Street analysts, Anixa Biosciences's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to ANIX previous annual EPS of $NaN (undefined).
Anixa Biosciences Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| INAB | IN8bio | $0.30 | $14.00 | 4566.67% | Buy |
| PMVP | PMV Pharmaceuticals | $1.50 | $24.75 | 1550.00% | Buy |
| ANTX | AN2 Therapeutics | $1.02 | $8.75 | 757.84% | Buy |
| CUE | Cue Biopharma | $0.59 | $5.00 | 747.46% | Buy |
| PYPD | PolyPid | $3.44 | $25.00 | 626.74% | Buy |
| AVTE | Aerovate Therapeutics | $1.90 | $13.00 | 584.21% | Hold |
| MOLN | Molecular Partners | $5.51 | $29.00 | 426.32% | Buy |
| INMB | INmune Bio | $5.88 | $22.00 | 274.15% | Buy |
| ANEB | Anebulo Pharmaceuticals | $1.80 | $6.00 | 233.33% | Buy |
| ANVS | Annovis Bio | $7.87 | $23.50 | 198.60% | Buy |
| RZLT | Rezolute | $4.35 | $12.50 | 187.36% | Buy |
| MLYS | Mineralys Therapeutics | $11.23 | $30.00 | 167.14% | Buy |
| ACRV | Acrivon Therapeutics | $8.08 | $21.50 | 166.09% | Buy |
| ANIX | Anixa Biosciences | $3.21 | $8.00 | 149.22% | Buy |
| IMNM | Immunome | $13.54 | $30.33 | 124.00% | Buy |
| ADAG | Adagene | $2.61 | $5.00 | 91.57% | Buy |
| ACLX | Arcellx | $71.25 | $61.00 | -14.39% | Buy |
ANIX Forecast FAQ
Is Anixa Biosciences a good buy?
Yes, according to 3 Wall Street analysts, Anixa Biosciences (ANIX) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 3 'Buy' recommendations, accounting for 100.00% of ANIX's total ratings.
What is ANIX's price target?
Anixa Biosciences (ANIX) average price target is $8 with a range of $8 to $8, implying a 149.22% from its last price of $3.21. The data is based on 3 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Anixa Biosciences stock go up soon?
According to Wall Street analysts' prediction for ANIX stock, the company can go up by 149.22% (from the last price of $3.21 to the average price target of $8), up by 149.22% based on the highest stock price target, and up by 149.22% based on the lowest stock price target.
Can Anixa Biosciences stock reach $5?
ANIX's average twelve months analyst stock price target of $8 supports the claim that Anixa Biosciences can reach $5 in the near future.
What are Anixa Biosciences's analysts' financial forecasts?
Anixa Biosciences's analysts financial forecasts for the fiscal year (Oct 2024) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-8.96M (high $-8.96M, low $-8.96M), average SG&A $0 (high $0, low $0), and average EPS is $-0.28 (high $-0.28, low $-0.28). ANIX's analysts financial forecasts for the fiscal year (Oct 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-14.104M (high $-14.104M, low $-14.104M), average SG&A $0 (high $0, low $0), and average EPS is $-0.44 (high $-0.44, low $-0.44).